Skip to main content

Table 5 Vitamin K agonist resumption

From: Reversal of Vitamin K Antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of Prothrombin Complex Concentrate (PCC) in current clinical practice

 

French guidelines

 
 

Non-valvular atrial fibrillation

Venous thromboembolic disease

Mechanical heart valve

 
 

Should definitively stop taking VKA after ICH

Bridging anticoagulation period; VKA resumption to be discussed

Bridging anticoagulation period; eligible to resume long-term VKA

 

Overall population

   

Total

   Number

342

101

38

516

   VKA resumption

88 (25.7)

33 (32.7)

11 (28.9)

136 (26.4)

ICH

    

   Number

137

31

16

199

   VKA resumption

15 (10.9)

4 (12.9)

4 (25.0)

21 (10.5)

  1. Results are expressed as number (percentage). Results are presented in patients at day 15 after prothombin complex concentrate infusion. ICH, intracranial hemorrhage; VKA, vitamin K antagonist.